On May 26, during French President Macron’s state visit, Vietnam Vaccine JSC (VNVC) and French pharmaceutical leader Sanofi signed a pivotal agreement to transfer vaccine production technology to Vietnam. The deal, witnessed by Presidents Luong Cuong and Macron at Hanoi’s Presidential Palace, marks a major step in deepening bilateral cooperation in healthcare and science and technology sectors
The agreement will enable VNVC to domestically manufacture a range of Sanofi’s widely-used vaccines – such as Hexaxim, Tetraxim, Adacel, Imojev, Verorab, Menactra, Avaxim, Vaxigrip Tetra, and Typhim VI – via gradual technology transfers. Sanofi will also provide support in human resource development and quality control systems for vaccine research and production
Complementing this collaboration, VNVC is constructing a new Vaccine and Biologicals Factory in Long An province. The 26,000 m² facility, with an initial USD 80 million investment, is designed to meet WHO, EU, and FDA GMP standards and aims to produce up to 100 million doses annually, with operations targeted by late 2027.
VNVC CEO Ngo Chi Dung hailed the deal as a milestone that will boost Vietnam’s vaccine autonomy, reduce costs, enhance immunization coverage, and improve preparedness for future outbreaks. This initiative is also seen as a testament to Vietnam’s expanding private-sector role and global integration in life sciences.
This landmark partnership strengthens Vietnam’s health security and signifies growing Vietnam – France collaboration in high-tech healthcare, laying a foundation for scientific, industrial, and strategic advancement in the region.
(Source: Quan Doi Nhan Dan)
